Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ACTRIMS 2021 | Paraneoplastic etiology of myeloneuropathy

Divyanshu Dubey, MBBS, Mayo Clinic, Rochester, MN, discusses the findings of an observational study of myeloneuropathy in paraneoplastic neurologic syndromes (PNS). PNS are a group of neurological disorders resulting from autoimmune responses mounted against the nervous system during an antitumor immune response. To determine if myeloneuropathy is a presenting phenotype of PNS, disease features of 32 patients with myeloneuropathy and underlying cancer or onconeural antibody seropositivity were investigated. The study concluded that paraneoplastic etiologies should be considered when evaluating myeloneuropathies, as well commonly considered metabolic etiologies. This interview took place during the ACTRIMS Forum 2021.


Dr. Dubey has consulted for UCB, Immunovant and Astellas Pharma. All compensation for consulting activities is paid to Mayo Clinic. He has a patent pending for KLHL 11-IgG and LUZP4-IgG as markers of neurological autoimmunity and germ cell tumors.